Linscomb Wealth Inc. Acquires 154 Shares of Stryker Co. (NYSE:SYK)

Linscomb Wealth Inc. lifted its holdings in shares of Stryker Co. (NYSE:SYK) by 1.0% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 15,846 shares of the medical technology company’s stock after acquiring an additional 154 shares during the period. Linscomb Wealth Inc.’s holdings in Stryker were worth $5,705,000 as of its most recent filing with the SEC.

Other institutional investors have also made changes to their positions in the company. Assenagon Asset Management S.A. grew its stake in shares of Stryker by 15.6% in the 3rd quarter. Assenagon Asset Management S.A. now owns 10,304 shares of the medical technology company’s stock valued at $3,722,000 after purchasing an additional 1,392 shares during the period. Arkadios Wealth Advisors boosted its stake in Stryker by 23.0% in the 3rd quarter. Arkadios Wealth Advisors now owns 732 shares of the medical technology company’s stock valued at $265,000 after buying an additional 137 shares in the last quarter. Strategic Blueprint LLC grew its position in Stryker by 5.8% in the third quarter. Strategic Blueprint LLC now owns 1,426 shares of the medical technology company’s stock valued at $515,000 after acquiring an additional 78 shares during the period. Valmark Advisers Inc. raised its stake in Stryker by 16.4% during the third quarter. Valmark Advisers Inc. now owns 2,738 shares of the medical technology company’s stock worth $989,000 after acquiring an additional 386 shares in the last quarter. Finally, Mutual Advisors LLC lifted its holdings in shares of Stryker by 9.0% during the third quarter. Mutual Advisors LLC now owns 5,562 shares of the medical technology company’s stock valued at $2,002,000 after acquiring an additional 457 shares during the period. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Stryker news, Director Ronda E. Stryker sold 201,392 shares of the business’s stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $392.24, for a total value of $78,993,998.08. Following the completion of the transaction, the director now directly owns 3,642,075 shares of the company’s stock, valued at approximately $1,428,567,498. The trade was a 5.24 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Allan C. Golston sold 2,458 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total value of $941,586.06. Following the sale, the director now directly owns 14,895 shares in the company, valued at approximately $5,705,827.65. This represents a 14.16 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 5.90% of the company’s stock.

Stryker Stock Down 0.7 %

NYSE:SYK opened at $389.10 on Friday. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59. Stryker Co. has a 12-month low of $314.93 and a 12-month high of $406.19. The stock’s fifty day simple moving average is $380.06 and its 200-day simple moving average is $370.50. The firm has a market capitalization of $148.47 billion, a P/E ratio of 50.14, a P/E/G ratio of 2.93 and a beta of 0.96.

Stryker (NYSE:SYK) last issued its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter in the previous year, the company earned $3.46 EPS. Equities research analysts expect that Stryker Co. will post 13.47 earnings per share for the current year.

Stryker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be paid a $0.84 dividend. This represents a $3.36 annualized dividend and a yield of 0.86%. The ex-dividend date is Monday, March 31st. Stryker’s payout ratio is presently 43.30%.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on SYK. Morgan Stanley raised shares of Stryker from an “equal weight” rating to an “overweight” rating and upped their target price for the stock from $370.00 to $445.00 in a report on Monday, December 2nd. Citigroup reaffirmed a “buy” rating and set a $450.00 price objective on shares of Stryker in a research note on Wednesday. Royal Bank of Canada raised their price objective on shares of Stryker from $425.00 to $435.00 and gave the stock an “outperform” rating in a report on Wednesday, January 29th. Stifel Nicolaus increased their price target on Stryker from $400.00 to $440.00 and gave the stock a “buy” rating in a research report on Wednesday, January 29th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $442.00 price objective on shares of Stryker in a research report on Wednesday, January 29th. Five analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $422.15.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.